Cambridge, MA, United States of America

Nicolas Cedric Boyer

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 9.5

ph-index = 3

Forward Citations = 25(Granted Patents)


Location History:

  • Cambridge, MA (US) (2016)
  • Somerville, MA (US) (2016 - 2024)

Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
14 patents (USPTO):

Certainly! Here is the article about inventor Nicolas Cedric Boyer based on the provided data:

Title: Innovator Spotlight: Nicolas Cedric Boyer

Introduction:

Nicolas Cedric Boyer, an esteemed inventor based in Cambridge, MA, has made significant contributions to the field of pharmaceuticals with his innovative work and multiple patents.

Latest Patents:

Boyer's latest patents focus on the development of cyclic polypeptides for PCSK9 inhibition. These compounds have the unique ability to bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibit interactions between PCSK9 and the human low-density lipoprotein receptor (LDLR). His pharmaceutical compositions offer promising methods for reducing LDL cholesterol levels in individuals in need of such interventions.

Career Highlights:

Boyer has a remarkable portfolio of 12 patents to his name, showcasing his dedication to advancing biopharmaceutical research. He has been associated with renowned companies such as Ra Pharmaceuticals, Inc., and the prestigious Massachusetts Institute of Technology (MIT). His tenure at these institutions has been marked by groundbreaking discoveries and a commitment to driving innovation in the pharmaceutical industry.

Collaborations:

Throughout his career, Boyer has collaborated closely with industry experts and researchers to bring his inventions to life. Collaborators such as Alonso Ricardo and Zhong Ma have played a pivotal role in supporting Boyer's research endeavors, leading to successful partnerships and transformative outcomes in the field of biopharmaceuticals.

Conclusion:

In conclusion, Nicolas Cedric Boyer stands out as a visionary inventor who continues to push the boundaries of pharmaceutical innovation. His groundbreaking work in developing cyclic polypeptides for PCSK9 inhibition underscores his commitment to improving healthcare outcomes and advancing novel therapeutic solutions. Boyer's contributions to the field are truly commendable, and his patents serve as a testament to his expertise and ingenuity in biochemistry and drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…